PT-141, whose International Nonproprietary Name is bremelanotide, reached FDA approval in 2019 roughly two decades after the melanocortin arousal effect was first observed, making its development arc one of the longer and stranger in modern sexual medicine. The compound was never designed for sexual function at all: it descends from Melanotan II, a tanning peptide, and the sexual-response activity surfaced as an accident that redirected the entire program. That single pivot, from dermatology to sexual medicine, is what the rest of this history documents.
Bremelanotide (PT-141) originated as a shortened derivative of the tanning peptide Melanotan II and, after a suspended intranasal male-erectile-dysfunction program, was reformulated as a subcutaneous injection that gained FDA approval in 2019 as Vyleesi for premenopausal hypoactive sexual desire disorder.
Melanotan II is a synthetic cyclic heptapeptide built as a superpotent analog of alpha-melanocyte-stimulating hormone, created at the University of Arizona in the late 1980s and early 1990s to darken skin without ultraviolet exposure. Its central flaw as a tanning agent became its value as a sexual-medicine lead: because it activates several melanocortin receptor subtypes rather than only the pigmentation-linked MC1 receptor, it carried off-target effects on sexual function. Bremelanotide is the ring-opened, deaminated derivative that keeps strong MC3 and MC4 activity while losing much of the MC1 pigmentation potency.
| Property | Melanotan II | Bremelanotide (PT-141) |
|---|---|---|
| Original purpose | Pharmacological tanning, skin-cancer protection | Sexual-response agent |
| Structure | Cyclic heptapeptide, C-terminal amide | Ring-opened, deaminated derivative |
| Receptor activity | Nonselective across melanocortin subtypes | Retains MC3/MC4, reduced MC1 |
| Dominant effect | MC1-driven pigmentation | MC3/MC4-mediated sexual response |
Bremelanotide is the shortened, ring-opened derivative of Melanotan II that preserves activity at the MC3 and MC4 receptors linked to sexual response while shedding much of the MC1 receptor activity that drives skin pigmentation.
The arousal effect was not predicted by a hypothesis; it surfaced as an incidental finding during early human exposure to Melanotan II, most notably in self-experimentation tied to the University of Arizona effort in the 1990s. What made the signal scientifically compelling was its origin: unlike vascular drugs that act on penile blood flow at the periphery, the melanocortin effect appeared to act centrally in the brain, on the neural pathways that govern desire and arousal. That distinction reframed a tanning side effect as a lead on a mechanism no other class addressed.
The sexual-response activity of the melanocortin peptide was documented as an unplanned side effect of Melanotan II during 1990s human self-experimentation, and its apparent central, brain-level action distinguished it from peripheral vascular erectile-dysfunction drugs.
The intranasal male-erectile-dysfunction program stalled on a cardiovascular safety signal that a quality-of-life drug cannot carry: mid-2000s trials recorded transient but meaningful increases in blood pressure. The delivery route was central to the problem, because intranasal absorption produced a rapid concentration spike, and the pressor effect was concentration-dependent. For an on-demand ED drug aimed largely at older men who often already have hypertension and cardiovascular disease, even a temporary blood-pressure excursion was disqualifying.
The intranasal male-erectile-dysfunction program was suspended in the mid-2000s after trials documented transient, concentration-dependent increases in blood pressure driven by the nasal route's rapid absorption spike, a risk considered disqualifying for an older, cardiovascular-compromised ED population.
The repositioning rested on matching the drug's central mechanism to a disorder defined by low desire rather than a mechanical failure of arousal. Because bremelanotide acts on brain melanocortin pathways that modulate desire rather than on genital blood flow, it fit hypoactive sexual desire disorder in a way vascular ED drugs could not. The developer paired that rationale with a lower-dose subcutaneous injection, trading the nasal absorption spike for a gentler exposure curve that kept the blood-pressure effect within a monitorable range.
| Design element | Intranasal ED program | Repositioned HSDD program |
|---|---|---|
| Route | Intranasal spray | Subcutaneous self-injection |
| Dose | Higher, rapid peak | Substantially lower, gentler curve |
| Indication | Male erectile dysfunction | Acquired, generalized HSDD |
| Population | Older men, often hypertensive | Premenopausal women |
| Use model | On-demand | On-demand, dosed before activity |
The compound was repositioned from a high-dose intranasal male-erectile-dysfunction drug to a lower-dose subcutaneous on-demand injection scoped narrowly to premenopausal women with acquired, generalized hypoactive sexual desire disorder, a desire disorder its central melanocortin mechanism fit better than any vascular drug.
The RECONNECT program ran two parallel, randomized, double-blind, placebo-controlled phase 3 studies of the subcutaneous on-demand formulation in premenopausal women with acquired, generalized hypoactive sexual desire disorder. It used validated patient-reported instruments as co-primary endpoints, measuring change in sexual desire and change in the distress tied to low desire. The trials showed a statistically significant benefit over placebo on both endpoints, though the absolute improvement was modest, a limit that later shaped much of the clinical debate about how meaningful the effect is in practice.
The two RECONNECT phase 3 trials established a statistically significant but modest improvement in sexual desire and desire-related distress over placebo, with a transient blood-pressure effect and common adverse events of nausea, flushing, headache, and injection-site reactions.
Approval came in 2019, when the FDA cleared bremelanotide under the brand name Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women, self-administered subcutaneously about forty-five minutes before anticipated activity. The label kept the trials' tight population definition, excluding low desire from a coexisting condition, relationship problems, or another medication, and excluding postmenopausal women entirely. Consistent with the molecule's history, the approval advised against use with uncontrolled hypertension or known cardiovascular disease, flagged an interaction with oral naltrexone, and capped dosing.
The FDA approved bremelanotide as Vyleesi in 2019 for premenopausal acquired, generalized hypoactive sexual desire disorder, with a label that limits use to no more than one subcutaneous dose per 24 hours and eight per month, advises against uncontrolled hypertension and known cardiovascular disease, and flags an interaction with oral naltrexone.
The molecule was carried from its melanocortin roots to approval by Palatin Technologies, a company built around the melanocortin receptor system as a drug-discovery platform, which is why it treated the intranasal failure as a reformulation problem rather than the end of the asset. Rather than shelve the compound after the blood-pressure wall, the developer redesigned the dose and route and re-scoped the indication toward female HSDD. That persistence, more than a single lucky compound, is what turned a stalled program into an approved medicine.
Palatin Technologies, a company built around the melanocortin receptor system, carried the peptide from a failed intranasal erectile-dysfunction program through reformulation and re-scoping to the 2019 approval, then commercialized it through a licensing partner while treating the result as validation of its melanocortin platform.
Alongside its regulated path, the peptide moved into a parallel underground economy, sold as a lyophilized powder by online research-chemical vendors and typically labeled not for human consumption to sidestep drug regulation. That research-chemical framing is the loophole, letting suppliers ship a pharmacologically active peptide without the manufacturing controls, prescriptions, or oversight a licensed medicine requires. The published record documents substantial hazard here, because unscreened users inject a compound with a known blood-pressure effect at doses that often run above the approved caps.
PT-141 circulates in a gray-market research-chemical economy where it is sold as a lyophilized powder labeled not for human consumption, self-administered without medical screening and frequently above the approved caps of one dose per 24 hours and eight per month, adding contamination and mislabeling risk to the drug's documented cardiovascular and hyperpigmentation effects.
Educational use only. This article describes what the published scientific and clinical literature reports about PT-141 (bremelanotide). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
